Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?

The presence of vasoactivity in rosacea-affected skin led to the development of two topical α-adrenergic receptor agonists, brimonidine tartrate 0.5% gel and oxymetazoline hydrochloride 1% cream, both approved by the United States Food and Drug Administration for treatment of persistent facial eryth...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Aesthet Dermatol
Autor principal: Del Rosso, James Q.
Format: Artigo
Idioma:Inglês
Publicat: Matrix Medical Communications 2017
Matèries:
In Focus
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605221/
https://ncbi.nlm.nih.gov/pubmed/29104721
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars